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Abstract 
 
The Aurora Kinase proteins are a family of serine/threonine kinases that have been shown to 
play fundamental roles in controlling M phase progression in somatic cells. Aurora Kinase A protein is 
known to be vital for proper spindle assembly and therefore, chromosome segregation. Previous 
reports have shown that Aurora Kinase B is vital for proper completion of karyokinesis and 
cytokinesis in somatic cells. The role of Aurora Kinase C in somatic cells has been found to be less 
clear; however it appears to play an important role in spermatogenesis. Little is known about the role 
of these Aurora Kinase proteins mouse oocytes during oogenesis, and even less is known about them 
in embryos during early development. The objective of these studies was to characterize the 
presence, localization, and function of Aurora Kinase B and Aurora Kinase C protein and mRNA in 
mouse oocytes and early embryos.  
Oocytes and embryos were collected from hormone stimulated CF-1 mice and cultured for 
varying amounts of time. Cumulus denuded oocytes were either fixed for immunofluorescence 
microscopy studies, lysed for analysis of mRNA levels through the use of reverse transcription PCR 
(rtPCR) and quantitative rtPCR (q-rtPCR), lysed for protein analysis employing Western blotting, 
treated with Aurora Kinase protein inhibitor drugs, or microinjected with a siRNA pool targeting 
Aurora Kinase B. Samples were processed for immunofluorescence analysis using markers of spindle 
morphology (tubulins), Aurora Kinase B, Aurora Kinase C, and Aurora Kinase B activity (phospho 
Histone H3). Analysis of relative levels of Aurora Kinase B and Aurora Kinase C mRNA were assessed 
by rtPCR and q-rtPCR methods. Western blotting was performed on oocytes and early embryos to 
quantitate Aurora Kinase B and C protein levels. Aurora Kinase inhibitors, Hesperadin and ZM447439, 
were added to culture medium with mouse oocytes to determine the effects of the loss of Aurora 
Kinase activity. siRNAs were used to inhibit Aurora Kinase B mRNA in early embryos to ascertain the 
effect of functional loss of this transcript on embryo development.   
Marked differences were observed in the localization of Aurora Kinase B when unfertilized 
oocytes or pre-zygotic genome activation (ZGA) embryos were compared to post-ZGA samples. There 
was no evidence of Aurora Kinase B protein localized to the mitotic spindle or resultant midbody in 
oocytes and blastomeres of early embryos. Western blotting results supported this data. Embryos 
fixed post-ZGA demonstrated Aurora Kinase B localization at midbodies between dividing cells, as 
was found in mouse embryonic fibroblast control cells. Aurora Kinase C protein was not 
demonstrable in mouse oocytes, embryos, or control cells using immunocytochemistry or Western 
techniques. In contrast, Aurora Kinase B and Aurora Kinase C mRNAs were both found to be present 
in mouse oocytes and early embryos. q-rtPCR data further supported this finding for Aurora Kinase B 
and revealed that the mRNA level of this transcript is relatively constant until ZGA  at which point a 
decrease relative to the earlier stages was observed. Transcript levels recovered post-ZGA and were 
comparable to the pre-ZGA levels. Functional inhibition of the Aurora Kinase family through the use 
of Hesperadin or ZM447439 demonstrated the importance of these proteins for proper microtubule 
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and spindle organization, as these drugs disrupted both karyokinesis and cytokinesis in mouse 
oocytes and blastomeres of early embryos. Aurora Kinase B targeting siRNA also established a role 
for Aurora Kinase mRNA in embryos at the 2-cell stage based on the disruption of the cell cycle that 
was observed in treated embryos.  
Given earlier reports showing the vital role of the Aurora Kinase proteins in proliferating 
somatic cells, knowledge of the expression and localization of these proteins in oocytes and early 
embryos is vital for the understanding of cell cycle control during oogenesis and early 
embryogenesis.  Our data indicate that Aurora Kinase B mRNA may also play a role in early 
embryogenesis, demonstrating a need for analysis of transcript as well as protein. Our results, as well 
as outcomes of future experiments suggested by our work, may provide significant insight into cell 
cycle regulation differences between somatic and embryonic cells. These differences may have a 
profound impact upon manipulated embryos including those reconstructed through somatic cell 
nuclear transfer. 
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Chapter 1: Introduction & Background 
 
The Aurora Kinase family is comprised of 3 serine/threonine kinase proteins in 
mammals – Aurora Kinase A, B, and C. While each member is a distinct protein, a high 
degree of homology exists within the family and their functions in the cell are similar, but 
not entirely complimentary. All three kinases have integral roles in proper assembly of the 
tubulin spindle, accurate segregation of chromosomes, and completion of cytokinesis to 
form two daughter cells (Carmena and Earnshaw, 2003; Bolanos-Garcia, 2005). The 
respective roles of the Aurora Kinases are fairly well established in somatic cells, but far less 
is known about their function or importance in gametes and early embryo genesis (Carmena 
and Earnshaw, 2003). Given that cell cycle defects are often observed in early development 
when oocytes and embryos are grown in vitro (Rizos et al., 2008), a greater understanding of 
the roles of Aurora Kinases in these cells may be significant in the pursuit to develop more 
successful oocyte and embryo manipulation techniques including culture and somatic cell 
cloning.  
The Aurora Kinase Family 
The first Aurora Kinase was found in Saccharomyces cerevisiae yeast and dubbed 
“increase in ploidy 1” or Ipl1 due to the uneven chromosome numbers found in mutants 
(Bolanos-Garcia, 2005). Slightly higher order organisms, such as Drosophila, C. elegans, and 
Xenopus, have evolved two distinct Aurora Kinase proteins, A and B, which function 
independently from one another. In this group of organisms Aurora Kinase A is most similar 
in sequence and function to the original yeast Ipl1. Mammals have three Aurora Kinases, 
known as Aurora Kinase A, B, and C (Carmena and Earnshaw, 2003). The three kinases share 
activating phosphorylation sites in the T-loops, D-box domains to promote degradation of 
the proteins at the end of mitosis, and N-terminal regulatory domains that control the 
activity of the Aurora Kianses (Fig 1, Quintás-Cardama et al., 2007). Aurora Kinase A in 
mammals appears to have maintained many of the same properties found in lower order 
organisms. Mammalian Aurora Kinases B and C have an extremely high degree of homology, 
75% in humans, and seem to share the role of Aurora Kinase B observed in organisms lacking 
Aurora Kinase C (Quintás-Cardama et al., 2007). The high degree of homology shared 
amongst the mammalian Aurora Kinases is suggestive of their common ancestral 
background, although they have been found to each play a distinct and important role in the 
proper progression of M phase (Bolanos-Garcia, 2005).  
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Figure 1: Homology of human Aurora Kinase proteins. Adapted from Quintás-Cardama et al., 2007. 
 
Aurora Kinase A has been extensively studied in somatic cells (Bolanos-Garcia, 2005). 
Human Aurora Kinase A is found on the centrosomes at initiation of mitosis and at the poles 
of the tubulin spindle once it has been assembled (Fig 2A & B). Observations of Drosophila 
cells with a mutated form of the Aurora homologue were found to display monopolar 
spindles. These deformed spindles were deemed responsible for the aberrant chromosome 
numbers in daughter cells (Glover et al., 2005). In mammals the role of Aurora Kinase A is 
very similar to what has been found in yeast and flies, despite the presence of three distinct 
Aurora proteins. Aurora Kinase A is known to be found on centrosomes in early M-phase and 
remains centrosome associated throughout the completion of cell division. Mammalian 
somatic cells lacking functional Aurora Kinase A exhibit abnormally shaped spindles without 
two distinct poles, which eventually lead to improper segregation of the chromosomes at 
anaphase (Gopaland et al., 1997).  
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Figure 2: Localization of the Aurora Kinase proteins in somatic cells. Tubulin is shown in green, chromatin in 
blue. A, Aurora Kinase A is shown in red at the poles of the spindle in a metaphase stage cell. B, Aurora Kinase 
A is shown in red at the poles of the disintegrating spindle in a late telophase cell. C, Aurora Kinase B is shown 
in red co-localized with chromatin at the metaphase plate in a metaphase stage cell. D, Aurora Kinase B is 
shown in red at the center of the spindle in an anaphase cell. Aurora Kinase C is not shown, but is identical to 
the Aurora Kinase B localization depicted. Adapted from Vader and Lens, 2008. 
 
 
The role of Aurora Kinase A in mammalian oocytes has been investigated and found 
to be much the same as in somatic cells (Yao et al., 2004). In mouse oocytes prior to MI 
Aurora Kinase A is found enriched in microtubule organizing centers (MTOCs) and as the 
spindle is assembled it is then observed at the spindle poles. Levels of Aurora Kinase A 
expression appear to remain stable, but abundant throughout meiosis (Saskova et al., 2008). 
When the protein was inhibited with monoclonal antibodies a variety of deformed spindles 
were observed (Fig 3). The majority of spindles appeared to have no poles, and mono-polar 
and misshapen spindles were also seen. These spindle abnormalities ultimately lead to 
unequal chromosome migration and aneuploidy in the absence of Aurora Kinase A (Yao et 
al., 2004). 
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Figure 3: Mouse oocytes microinjected with Aurora Kinase A monoclonal antibody and stained for Tubulin 
(green) and chromatin (red). A, control oocyte injected rabbit IgG. Normal spindles observed in this group. B-F, 
experimental oocytes injected with Aurora Kinase A monoclonal antibody. Varied abnormal spindles observed 
in this group. Adapted from Yao et al., 2004. 
 
In somatic cells Aurora Kinase B is an important member of the chromosomal 
passenger complex (CPC), along with Survivin, INCENP, and Borealin. While the individual 
members of the complex are responsible for localization, interaction with targets, and 
complex morphology, Aurora Kinase B is responsible for phosphorylating and activating a 
wide variety of substrates including serine 10 of Histone H3, mitotic centromere-associated 
kinesin, and vimentin among others (Vader et al., 2006). Immunohistochmistry and Western 
blotting have shown that Aurora Kinase B protein levels are at their peak in cells that are 
currently undergoing M phase. Staining shows that it is found on condensed chromosomes 
in the kinetochore region though metaphase (Fig 2C, Fig 4Ba). At the kinetochore, Aurora 
Kinase B plays a pivotal role in the progression of M phase by recognizing monotelic and 
syntelic attachment of sister chromatids to the spindle microtubules. Advancement of 
mitosis beyond metaphase is prevented until these attachments are corrected (Tanaka et al., 
2002). After metaphase is exited, Aurora Kinase B protein can be found in the center of the 
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spindle and on the spindle midbody as cytokinesis occurs (Fig 2D, Fig 4Ca & Da). This 
dynamic localization has much to do with the protein’s several roles as M-phase progresses. 
A role for Aurora Kinase B in cytokinesis completion has also been demonstrated. Aurora 
Kinase B is responsible for phosphorylating several proteins at the cleavage furrow including 
MgcRacGP which is essential for the final steps of cytokinesis (Carmena & Earnshaw, 2003). 
 
 
Figure 4: Aurora Kinase B (green) localization in HeLa cells undergoing mitosis. Tubulin (red) and chromatin 
(blue) are also stained. Scale bar represents 5 μm. Adapted from Ruchaud et al., 2007. 
 
Aurora Kinase B has been studied in the oocytes of several species. Through the use 
of a fluorescent recombinant Aurora Kinase B protein, the localization of the protein has 
been studied in mouse oocytes. The protein was found co-localized with centromeres during 
metaphase I and as meiosis I progressed was found to remain localized to the midbody. 
Localization was not found to be the same through meiosis I, but rather the protein was 
distributed throughout the cytoplasm (Shuda et al., 2009). In Xenopus laevis oocytes, Aurora 
Kinase B activity, via Histone H3 phosphorylation, was found to rapidly increase after 
treatment with progesterone and subsequent germinal vesicle breakdown. Although a 
functional role and localization of the protein was not described, it was determined that the 
activity of Aurora Kinase B is activated by the presence of INCENP, one of the other CPC 
proteins (Yamamoto et al., 2008). The role of Aurora Kinase B in meiosis has also been 
studied in oocytes of surf clams (Spisula solidissima). It was found that inhibition of Aurora 
Kinase B through the use of Hesperadin, a pharmaceutical Aurora Kinase inhibitor, resulted 
in chromatin decondensation, Histone H3 dephosphorylation, chromosome segregation 
defects in meiosis II, and finally the absence of the formation of the second polar body 
(Georget et al., 2006).  Taken as a whole, these studies show some similarities of Aurora 
Kinase B function and localization in cells undergoing meiosis and mitosis. There are also 
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several distinct differences noted in the protein’s role in meiosis I and II revealing that 
meiosis and mitosis are not controlled or orchestrated identically.  
In comparison to Aurora Kinase A and B, less is known about the roles and functions 
of Aurora Kinase C. This is in part due to the fact that Aurora Kinase C is very highly 
homologous to Aurora Kinase B, making it difficult to accurately target in experimental 
studies. It has been demonstrated in HeLa cells that Aurora Kinase C protein can also be 
found as a member of the CPC, but is expressed in markedly lower abundance than Aurora 
Kinase B protein. Aurora Kinase C also has a much lower affinity for the other CPC members, 
further contributing to its more minor role. In the absence of Aurora Kinase B, Aurora Kinase 
C can compensate to some degree, but not completely. Some cells depleted of Aurora 
Kinase B protein are able to successfully divide and perpetuate, while the vast majority fail 
to perform a proper mitosis. This partial complementation is thought to be partly due to the 
lack of Aurora Kinase C protein quantity as well as the reduced complex affinity (Sasai et al., 
2004; Slattery et al., 2009). Aurora Kinase C has also been shown to have a role in the 
development of male gamete cells (Fig 5). Mouse sperm cells formed in the absence of 
Aurora Kinase C were found to have significantly more defects including decreased 
chromatin condensation and abnormal morphology than wildtype counterparts (Kimmins et 
al., 2007). A similar role for Aurora Kinase C in mouse oocytes has not been found. It remains 
unclear if Aurora Kinase C is vital for control of meiosis progression in all cells undergoing the 
process (oocytes and sperm), or if this activity is found in developing sperm cells alone.  
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Figure 5: Sperm observed by electron microscopy from either WT (+/+) or Aurora Kinase C mutant (-/-) mice. 
Asterisks show heterogeneous chromatin condensation, arrows show acrosome/head defects. Scale bar, 0.5 
μm. Adapted from Kimmins et al., 2007. 
 
Given the integral roles that the Aurora Kinase family proteins play in the process of 
cell division, it is not surprising that they have been found to be involved in cell cycle defects. 
Aurora Kinases were first implicated as potential oncogenes in 1998 when Aurora Kinase A 
was found to be overexpressed in more than 50% of primary human colorectal cancer cells 
(Bischoff et al., 1998). Numerous cancer cell types have since been investigated and all 
found to have abnormally high levels of Aurora Kinase proteins (Tbl 1). All three human 
Aurora proteins appear to have an association with cancer as each has been found altered in 
at least two types of cancer (Kollareddy et al., 2008). It is not clear if the upregulation is the 
cause of the disease or a result of it. Regardless, the Aurora Kinase proteins are currently a 
popular target for many promising new cancer treatments. The inhibition of the Aurora 
Kinase proteins through the use of several different pharmaceuticals has proven to be 
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sufficient to prevent further growth of tumors in vivo. Whether this avenue of treatment 
continues to be advantageous remains to be seen, but for now the Aurora Kinase proteins 
are of great interest in the fight against cancer (Gautschi et al., 2008).  
 
Aurora Kinase Tumor Type 
Aurora Kinase A 
 
Breast Cancer 
Human Gliomas 
Ovarian Cancer 
Prostrate Cancer 
Cervical Cancer 
Colon Cancer 
Pancreatic Cancer 
Lung Cancer 
 
Aurora Kinase B 
 
Colon Cancer 
Thyroid cancer 
Oral Cancer 
Non small cell lung carcinoma 
Breast cancer 
 
Aurora Kinase C 
 
Breast Cancer 
Liver Cancer 
 
 
Table 1: Over-expression or amplification of Aurora kinases has been found in a wide variety of tumors types, 
making them attractive targets for cancer therapy. Adapted from Kollareddy et al., 2008.
 
In vitro Manipulations of Mammalian Oocytes and Pre-Implantation Embryos 
In vitro maturation (IVM) of oocytes and subsequent culture of preimplantation stage 
embryos is an important technique for many reasons. The cattle industry relies upon gamete 
culture for embryo transfer between donors and recipients. This allows offspring to be 
produced from valuable donor animals without requiring down time for the donor. 
Superovulation of the donor prior to harvest and culture also makes it possible to produce 
several offspring per breeding cycle from a female that would normally produce only one 
oocyte. Any time pre-implantation manipulations of the oocyte or embryo are required, 
harvest and culture is also a necessity. These manipulations can include genetic screening, 
sex selection, disease prevention, somatic cell nuclear transfer, and many others. Human 
assisted reproduction clinics also regularly require successful culture of oocytes and embryos 
to produce viable embryos for transfer into recipients. Clearly being able to mature oocytes 
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and culture pre-implantation embryos in vitro and maintain viability is an essential technique 
for many applications related to fertility and infertility. Unfortunately, to date IVM is 
especially problematic in mammals and results in high loss rates (Hashimoto, 2009).  
While In vitro maturation of oocytes and pre-implantation embryos is required in the 
many instances previously mentioned, the technique has not been perfected. Many oocytes 
and embryos must be discarded because they exhibit signs of cell cycle defects that render 
them non-viable. These defects can be observed as cell fragmentation, failure of cell cycle 
progression and lysis of individual cells within the embryo. While cells with these gross 
morphological abnormalities are easily culled, culture also induces defects that are not easily 
detected in live samples. This can include aberrant gene expression profiles, post-
transcriptional changes, and other flaws that affect viability. The root cause of these defects 
is not entirely clear, although some gene expression abnormalities have been proven.  
Studies have shown that bovine oocytes matured in vitro often give rise to offspring 
with “abnormal offspring syndrome” (AOS). AOS includes subtle defects such as increased 
placenta weight and abnormal placental blood vessel development as well as more obvious 
neonatal development flaws such as increased size and dystocia at birth. AOS is observed in 
a wide variety of severities, making diagnosis of specific genes involved difficult, especially 
prior to embryo transfer (Farin et al., 2006).  Bovine oocytes have also been used to 
demonstrate the role of the cumulus-oocyte complex (COC) in the development of the 
oocyte. Oocytes denuded of cumulus cells immediate upon removal from the ovary, as is 
typically done as oocytes are harvested for research purposes, were shown to have 
significantly lower levels of luteinizing hormone receptor and follicle stimulating hormone 
receptor mRNA (Calder et al., 2005). Further studies on IVM in macaque oocytes has shown 
that insulin-like growth factor 2 protein, a growth factor required for early development, and 
steroidogenic acute regulator protein, a mitochondrial transport protein involved in steroid 
hormone production, are both significantly reduced in IVM oocytes. The reduction of both of 
these proteins has been remedied by supplementation with human recombinant growth 
factor and developmental competence in these treated oocytes is increased (Nyholt de 
Prada et al., 2010). Given these and other common defects of cultured oocytes and pre-
implantation embryos, elucidation of factors controlling the cell cycle in these cells is vital for 
understanding cell cycle regulation and future improvements in culture conditions that may 
yield a higher percentage of viable embryos. 
One of the reasons that the culture of oocytes and early embryos is particularly 
challenging is the enormous developmental changes that occur in the time period from 
ovulation to implantation (Fig 6). Ovulated oocytes must first resume meiosis, which occurs 
due to calcium oscillation signaling activated by sperm during fertilization (Ducibella et al., 
 17 
 
2002). Pro-nuclei are formed upon fertilization and eventually fuse to create one diploid 
nucleus in a one-cell embryo. Embryos then undergo another major modification – zygotic 
genome activation. This is the stage at which the embryo initiates mRNA transcription from 
its own genome rather than using maternal mRNA produced and stored in the oocyte during 
oogenesis. The exact stage at which this occurs is species dependant, but it is generally 
around the 2-cell stage (Schultz, 2005). In the stages just prior to implantation the embryo 
goes through further morphological changes and cell differentiation.  Compaction occurs, 
which establishes gap connections between blastomeres so that material may be 
transported and shared. Once compaction is complete, due to the gap junctions between 
blastomeres, the outer blastomeres become polarized as does the distribution of 
cytoplasmic and membrane bound factors. From this stage forward, polarity of the outer 
blastomeres is maintained and the cells of the embryo no longer have equal developmental 
potential. Following compaction, blastulation will commence. In order to form a proper 
blastula the trophectoderm and the inner cell mass must differentiate to form two distinct 
cell lineages (Marikawa and Alarcón, 2009). 
 
 
Figure 6: The in vitro development of a mouse embryo from fertilization to blastocyst formation. 2PB: second 
polar body, ZP: zona pellucida, TE: trophectoderm, ICM: inner cell mass. Scale bar = 50 mm. Adapted from 
Marikawa and Alarcón, 2009. 
 
While oocytes and pre-implantation embryos are attempting to perform these 
delicate transformations in the presence of imperfect culture conditions, many things can go 
wrong. When mouse embryos matured in vivo are compared to counterparts cultured in 
various media, many gene expression abnormalities are found (Fig 7). The vast majority of 
these changes result in down-regulation of expression, but in varying degrees (Ho et al., 
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1995). These modifications, while small, are not insignificant. Many of the genes involved 
play roles in cell proliferation, protein synthesis, apoptosis, and trafficking; consequently, 
they are very important in the earliest stages of development. Small changes in the 
expression patterns of these genes, aquaporin 8 (Aqp8) which is involved in transport of water 
and solute carrier 7 and 15 (slc7, slc15) which are involved in the transport of molecules 
across membranes, and can negatively impact embryo viability. Embryos grown in different 
culture media show different gene expression alterations, but none appear to approximate 
conditions in vivo (Rinaudo and Schultz, 2004). While this research has provided insight into 
changes induced by the micro-environment, little progress has been reported to mitigate the 
perturbations. 
 
 
Figure 7: Three genes exhibiting decreased expression in embryos cultured in multiple media, assayed via 
multiple methods to confirm results. Aqp8 – aquaporin 8, Slc7 – solute carrier family 7, Slc15 – solute carrier 
family 15. IV: in vivo, KSOM/AA: KSOM/AA medium, WM: Whitten’s medium, MA: microarray analysis, RT: 
rtPCR analysis. Rinaudo and Schultz, 2004.  
 
While the Aurora Kinase family is fairly well characterized in somatic cells of many 
species, little is known about these proteins in gametes, and even less is known about their 
role during meiosis and early embryo development. When oocytes and embryos are 
matured in vitro, and it is common to see a high percentage of these embryos arrest cell 
division and cease to develop, rendering them non-viable. These losses are problematic in 
human fertility clinics as well as research laboratories focused on mammalian oocytes and 
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embryos (Rizos et al., 2008). Previous attempts have been made to increase efficiency of in 
vitro maturation of mouse oocytes in a strain dependent manner. It was shown that the 
most efficient agent to reactivate meiosis after the metaphase II checkpoint in oocytes is 
strain dependent and the timing of completion of meiosis also depends heavily upon the 
strain of mouse. This demonstrates oocytes are heavily affected by treatment and culture 
conditions and subtle differences in protocol may result in significant differences in 
efficiency (Ibáñez et al., 2005). 
Manipulation of oocytes for somatic cell nuclear transfer (SCNT) requires the cell 
cycle of the oocyte to continue despite the addition of a somatic nucleus. Embryos 
reconstructed through SCNT are often observed to have cell cycle defects or developmental 
arrest. Yoo et al. were unable to produce reconstructed SCNT rat embryos that developed 
beyond the 2-cell stage despite several variations of the SCNT protocol. Further investigation 
revealed abnormal microtubule distribution and organization in the reconstructed embryos 
which likely did not allow for further development due to the inability to assemble a proper 
spindle (Yoo et al., 2007).  Similarly, nonhuman primate SCNT embryos showed increased 
competency with enucleation just prior to the metaphase II arrest, but reconstructed 
embryos remained inferior to in vivo fertilized controls. This was attributed to spindle 
defects that resulted in aneuploid embryos among other factors, including improper 
reprogramming of the chromatin (Simerly et al., 2004).  
Drastic changes to the SCNT protocol, including chemically induced enucleation, have 
been attempted. Demecolcine, a microtubule depolymerization agent, can be used to 
disrupt the metaphase spindle in a metaphase II stage oocyte. This yields chromatin that 
remains in a single cluster and ultimately completely extrudes from the oocyte in the second 
polar body. The resultant cytoplast can then be used for nuclear transfer to reconstruct a 
cloned embryo. Although this procedure eliminates the first mechanical manipulation of the 
oocyte, its efficiency remains relatively low at 23-70%. In the oocytes that do not complete 
extrusion of the second polar body, a protrusion of the plasma membrane is often observed, 
but the completion of cytokinesis never occurs (Fig 8, Ibáñez et al., 2003). Interestingly, the 
protrusion of the plasma membrane observed in these reconstructed embryos mimics the 
phenotype often observed in somatic cells deficient of Aurora Kinase B. In light of these 
findings, factors that control progression of the cell cycle and microtubule organization, such 
as the Aurora Kinase family, are of great interest for their possible implications in the 
inefficiency of SCNT.  
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Figure 8: A Demecolcine treated oocyte at 135 minutes post activation. A, Tubulin is stained in green, 
chromatin in blue. The first polar body is marked with the arrowhead. There are two partially extruded second 
polar bodies, each with chromatin. B, Actin is stained in red.  The second polar body has not completely 
extruded as evidenced by the absence of actin contact from either side of the plasma membrane. Adapted 
from Ibáñez et al., 2003.  
 
The possibility remains that some of the defects that result in the low efficiency of in 
vitro maturation of oocytes is due to aberrant expression or localization of the Aurora Kinase 
proteins. Therefore, elucidation of the role of the Aurora Kinases in in vivo matured 
mammalian oocytes and early embryos is of great importance due to the cell cycle defects 
that are commonly observed in in vitro cultured and manipulated cells. The similarities of 
phenotypes observed in cells depleted of Aurora Kinase proteins and in manipulated or IVM 
oocytes make the Aurora Kinase proteins especially attractive to study. Understanding the 
correct expression and localization of the Aurora Kinase proteins in oocytes and pre-
implantation embryos will allow for further investigation of the Aurora Kinases in 
manipulated or in vitro cultured samples.  
 
Thesis Objectives 
 The studies described in this thesis were designed to reveal the localization and 
function of Aurora Kinase B and C in mouse oocytes and early embryos. In vitro matured 
oocytes and embryos were used to study the proteins of interest through the progression 
and completion of meiosis as well as during the initial mitotic divisions of blastomeres of 
preimplantation stage embryos.  
It was hypothesized that:  
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1. Aurora Kinase B and C would be expressed and localized in oocytes and embryos 
similarly to the localization previously reported for somatic cells. Likewise, 
presence of mRNA transcript for these genes would mimic the pattern 
established in somatic cells.  
2. Upon loss of function of Aurora Kinase B or C there would be cell cycle defects 
similar to those previously observed in somatic cells depleted of either protein.  
 
Several approaches were employed to answer these questions. Localization of the 
protein was attempted through the use of immunocytochemistry with primary antibodies 
targeted to the proteins of interest and secondary antibodies with fluorescence tags. 
Presence and relative quantification of the proteins was determined with Western blotting. 
The presence and relative quantification of mRNA gene transcripts was determined using 
reverse transcriptase PCR (rtPCR) and quantitative rtRCR respectively. The function of Aurora 
Kinase B and C in mouse oocytes and embryos was determined with a combination of 
specific chemical inhibitors and siRNA constructs designed to target individual mRNA 
transcripts.  
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Chapter 2: Aurora Kinase B 
Materials & Methods 
Oocyte/Embryo Collection & Culture 
CF-1 female mice (8-12 weeks, Charles River, MA) were superovulated with 5 IU eCG 
(Calbiochem #367222) intraperitoneally followed 48h later with 5 IU hCG (Calbiochem 
#230734) intraperitoneally. Germinal vesicle stage oocytes were collected from ovarian 
follicles 46h post-eCG injection. Ovulated MII oocytes were collected from oviducts 14-16h 
post hCG injection. Embryos were produced by mating superovulated females with CF-1 
males overnight. Embryos were then harvested from the oviducts into FHM medium 
(Millipore #MR-024-D, see Appendix A) 14-16h post-hCG injection. Oocytes or embryos 
surrounded by cumulus cell masses were briefly treated with hyaluronidase (Sigma #H-3884) 
and gently pipetted to remove the cumulus cells and washed 3 times in FHM medium. 
Oocytes were cultured in medium for four hours with 10mM strontium chloride (SrCl2, Sigma 
#S-0390) to parthenogenetically active them as necessary (Ibanez et al., 2005). Samples 
were randomly assigned to groups for either immediate processing or further culture in 
KSOM medium (Millipore #MR-106-D, see Appendix A). Culture was performed in humidified 
chambers at 37°C, 5% CO2 in air for various lengths of time.  
Immunocytochemistry 
Mouse oocyte and embryo samples were fixed in several different solutions: 1) 1% 
paraformaldehyde and 0.15% triton X-100 (see Appendix A) for 30m at 37°C, 2) MTSB-XF 
solution (see Appendix A) for 30m at 37°C, or 3) ice cold methanol for 5m on an ice block. 
Regardless of fixation method all samples were subsequently stored at 4°C in 
immunocytochemistry blocking solution (see Appendix A) until being further processed. 
Microscopy with probes for Aurora Kinase B (AurB), microtubules (Tub), and chromatin was 
performed. Aurora Kinase B was detected with primary polyclonal rabbit anti-AurB antibody 
(Abcam #ab2254, 1:500 dilution). The primary AurB probe was followed by a secondary 
Alexa fluor 594 labeled goat anti-rabbit antibody (Invitrogen #A11072, 1:400 dilution). A 
mixture of primary monoclonal anti-α-tubulin and anti-β-tubulin antibodies (Sigma-Aldrich 
Co #T-9026 and #T-4026 respectively, 1:1000 dilution) followed by a secondary Alexa fluor 
488 labeled goat anti-mouse antibody (Invitrogen #A21121, 1:400 dilution) was used to label 
microtubules. Chromatin was labeled with 10μg/ml of Hoechst 33258 (Molecular Probes #H-
1398). Labeled eggs were then mounted onto slides in a mounting solution of 50% glycerol in 
PBS with sodium azide and covered with a glass coverslip. Samples were analyzed using a 
Zeiss Axiovert 200M inverted microscope coupled to a Roper CoolSnapFx high resolution 
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CCD camera. Images were captured and rendered in real time using Axiovision software. 
Mouse embryonic fibroblasts were used as positive controls.  
 
Western Blotting 
 For protein expression analysis by western blotting Mouse oocytes or embryos for 
were lysed using a mammalian cell lysis kit (Sigma-Aldrich Co #MCL-1). Cells were added to 
the solution, vortexed vigorously, and stored at -20°C. Prior separating proteins by 1-D PAGE, 
samples were briefly thawed at room temperature, mixed 50:50 with Laemmli sample buffer 
(BioRad #161-0737) containing 3% β-mercaptoethanol. Samples were then boiled in a 100°C 
heat block for at least 5m and loaded onto a 12% polyacrylamide gel (VWR #81002-028). 
Rainbow Molecular Weight Markers (Amersham Biosciences #RPN800E) were used to 
determine protein separation and estimate molecular weight. Gels were run at 150V, 100mA  
until marker bands were appropriately separated. Transfer of the protein to ECL+ membrane 
(Amersham Biosciences #RPN68D) was performed using a wet apparatus with 40V of current 
for 90m and membranes were then stored in Western blocking solution (see Appendix A) at 
4°C until analyzed.  
 Membranes were washed 3x with TBS-T solution and then probed with AurB 
polyclonal antibody (Abcam #ab2254, 1:1500) in TBS-T for 1h at room temperature. 
Membranes were washed as previously described, and then probed with anti-rabbit-HRP 
secondary antibody using the Visualizer Western blotting kit (Upstate #64-202). Membranes 
were washed again and chemiluminescent detection was performed using the Visualizer 
Western blotting kit as described and ECL+ film (Amersham Biosciences #28-9068-35).  
Histology 
 Samples of mouse ovary tissue were fixed in 10% formalin solution (Newcomer 
Supply #1090) and paraffin embedded and processed by the Worcester Polytechnic Institute 
histology core facility. 5μm sections were mounted on slides and de-paraffinized via xylene 
and ethanol baths followed by rehydration in water. Sections were then stored overnight at 
RT in blocking solution. Protein localization was done using a primary polyclonal Aurora 
Kinase B antibody (Abcam #ab2254, 1:500) for 60m at 37°C in a humidified chamber, 
washed, and a secondary Alexa fluor 594 labeled goat anti-rabbit antibody (Invitrogen 
#A11072, 1:400 dilution) for 60m at 37°C in a humidified chamber. Chromatin was labeled 
with 10μg/ml of Hoechst 33258 (Molecular Probes # H-1398) at RT for 10m. Samples were 
washed in PBS/PVP between staining steps. Samples were sealed with a coverslip and 
analyzed using a Zeiss Axiovert 200M inverted microscope coupled to a Roper CoolSnapFx 
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high resolution CCD camera. Images were captured and rendered in real time using Zeiss 
Axiovision software. Testis samples were used as a positive control. 
Reverse Transcriptase PCR 
Total RNA was extracted from mouse oocyte and embryo samples for reverse 
transcriptase PCR (rtPCR) with the Stratagene Absolutely RNA Nanoprep kit (Stratagene 
#400753). cDNA was produced from extracted RNA through the use of the SuperScript First 
Strand Synthesis System (Invitrogen #12371-019) and PCR was performed using intron 
spanning primers specific to Aurora Kinase B and β-actin. Several primer pairs were 
evaluated and the primer pair which yielded the most robust reaction was utilized in 
subsequent analyses. Aurora Kinase B primers used were: cctgaaacatcccaacatcc and 
ctccctgcagacctaacagc. β-actin primers used were: tgttaccaactgggacgaca and 
ggggtgttgaaggtctcaaa. PCR cycle conditions were: 95°C 30 sec, 55°C 45 sec, 72°C 1 min, and 
30 cycles were run. Reaction products were run out on 2% agarose gels with Ethidium 
Bromide. All PCR products were of the expected size: β-actin = 165bp, Aurora Kinase B = 
245bp. Images were aquired using a Kodak Image Station 400MM and densitometry was 
performed using Adobe Photoshop. Aurora Kinase B products were normalized to β-actin. 
Quantitative Real Time Reverse Transcriptase PCR (q-rtPCR) 
 Oocyte and embryo samples (n=5/group) were lysed, treated with DNAse, and 
subjected to reverse transcription using the TaqMan Gene Expression Cells to CT kit (Ambion 
#4399002) as described. Samples were stored at -20°C until being processed further. 
Quantitative real time reverse transcriptase PCR was performed using an Applied Biosystems 
7500 Real-Time PCR System, TaqMan probes specific to Aurora Kinase B (Applied Biosystems 
#4331182- Mm01718140_m1), master mix solution provided in the Cells to CT kit, and 2.5μL 
reverse transcriptase product. All experimental samples were run in triplicate. Control 
reactions were performed with TaqMan probes specific to β-actin (Applied Biosystems 
#4331182-Mm00607939_s1), no reverse transcriptase product, and RNA only template in 
duplicate on every reaction plate. Data was collected and analyzed using the Applied 
Biosystems 7500 System software and Microsoft Excel.  
Loss of Function Experiments 
 Mouse embryos were collected from oviducts at the fertilized 1-cell stage and 
cultured as previously described for approximately 24h. Once divided to the 2-cell stage, 1 
blastomere of the 2-cell embryo was microinjected with a pool of three to five siRNA 
constructs specific to Aurora Kinase B (Santa Cruz Biotechnology, Inc. #sc-43532). 
Approximately 65pL of RNAi solution was injected into each blastomere and solution 
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concentrations of 57μM, 40μM, and 20μM were used. Injections were conducted using an 
Eppendorf PipetteMan microinjection system attached to a Zeiss Axiovert 200M inverted 
microscope. During the microinjection procedure embryos were held in FHM media droplets 
under oil in glass bottom dishes and transferred back to culture conditions as soon as 
possible. Control and experimental microinjections were performed in alternating order to 
mitigate any effect treatment timing may have. Controls were produced via microinjection 
of an inert pool of siRNA (Santa Cruz Biotechnology, Inc. #sc-37007) and embryos introduced 
to the condition changes necessary for microinjection, but not treated. Embryos were 
cultured (37°C, 5% CO2 in air) for 24h or 48h following microinjection and then processed for 
immunocytochemistry or q-rtPCR.  
 
Results 
Localization of Intracellular Aurora Kinase B protein in Oocytes and Embryos 
 Mouse oocytes and embryos were subjected to immunocytochemistry to determine 
what extent Aurora Kinase B protein was present or absent in the samples. If the protein was 
detectable, then localization characteristics were established. Oocytes and embryos prior to 
the 8-cell stage were found to have signal from the Aurora Kinase B probes displayed as 
homogeneous punctate staining throughout the cytoplasm (Fig 9b and c). From the 8-cell 
stage to blastocyst, the most developmentally advanced stage studied, Aurora Kinase B 
protein was observed on the midbody as cells complete the last steps of cytokinesis (Fig 9d-
f). As the midbody is narrowed further with increasing separation of the daughter cells 
Aurora Kinase B was localized to a decreasing focal point at the point of contact between the 
cells prior to excision. This was comparable to the localization observed in mouse embryonic 
fibroblast control cells (Fig 9a). These data suggest that prior to the 8-cell stage, Aurora 
Kinase B does not have a specific localization within the cell during any portion of the cell 
cycle. Similar results were obtained with three different fixation techniques, although the 
samples subjected to MeOH fixation were difficult to image as the native morphology was 
severely distorted.  
Quantification of Aurora Kinase B protein in Oocytes and Embryos 
 In conjunction with the immunocytochemisty studies Western blotting was 
performed in parallel experiments to determine if Aurora Kinase B was present in the oocyte 
and embryo samples. Relative amounts of protein were determined from samples subjected 
to Western blotting. Oocytes and embryos were collected in groups ranging from 10 to over 
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250 cells per sample. Mouse embryonic fibroblasts were used as positive controls. Initially a 
band of inappropriate size was detected when the blots were probed for Aurora Kinase B. 
This band was proven to be remnant bovine serum albumin from the medium that the 
oocyte and embryos were collected and cultured in prior to lysis. Vigorous washing of the 
samples in PBS prior to lysing eliminated the band during subsequent analyses. Despite the 
large numbers of cells lysed and extremely sensitive detection systems used, no Aurora 
Kinase B protein was found in the samples analyzed (Fig 10). In contrast, α/β-tubulin was 
easily detected in both experimental and control samples, which is most likely due to its high 
abundance. This control validated the lysis, blotting, and detection techniques and 
confirmed that Aurora Kinase B was likely absent or present at extremely low abundance.  
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Figure 10: Western blot of MII stage mouse oocytes and mouse embryonic fibroblasts (MEF) probed for Aurora 
Kinase B. There is a band visible of appropriate size for Aurora Kinase B (~37kD, arrow) in the MEF lane, yet no 
corresponding bands apparent in any of the oocyte sample lanes. The higher molecular weight band also visible 
in the MEF lane is residual tubulin signal from a previous probing. 
 
Localization of Intracellular Aurora Kinase B protein in Ovary and Testis Tissue 
 Histology was performed on mouse ovarian tissue to determine if Aurora Kinase B 
was present in oocytes within follicles prior to ovulation or in the cells directly surrounding 
the developing follicle. The ovarian samples analyzed displayed subtle staining in the red 
channel, which is indicative of Aurora Kinase B presence. The signal was observed primarily 
in the follicular cells surrounding developing oocytes (Fig 11). The staining within oocytes 
appeared very similar to the diffuse punctate pattern observed in ovulated oocytes. 
Unfortunately, a significant fluorescent background signal was observed in the green 
channel, indicating that the samples had high levels of autofluorescence. Much of the signal 
observed in the red channel also co-localized with the autofluorescence observed in the 
green channel. This raises the possibility that the observed red signal may not be due to 
Aurora Kinase B protein presence, but rather a result of autofluorescence. Testicular tissue 
was used as a control and it displayed much of the same autofluorescence that was detected 
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in ovarian tissue (Fig 9). Controls stained with the secondary antibody only did not hsow any 
evidence of non-specific binding. Accordingly, it is impossible to draw solid conclusions 
about the presence or absence of Aurora Kinase B in this tissue. Alternative methods of 
fixation and/or localization that do not rely upon fluorescent probes may be worth 
investigating in the future.  
 
Figure 11: Fixed sections of mouse ovary and testis stained for Aurora Kinase B (red) and chromatin (blue). 
Green signal represents autofluorescence. Scale bar represents ~40μm. 
 
Identification of Aurora Kinase B mRNA in Oocytes and Embryos 
 Non-quantitative reverse transcriptase PCR reactions were performed on oocyte and 
embryo lysate samples to determine that Aurora Kinase B mRNA was present. Oocytes 
(germinal vesicle to MII, and MII to SrCl2 activated stage) were analyzed as well as embryos 
from the one-cell to four-cell stages. Aurora Kinase B mRNA was detected in all of the stages 
of oocytes and embryos tested (Fig 12a). All samples were analyzed for the presence of β-
actin as a control for the assay (Fig 12b). Densitometry analysis was used to normalize 
Aurora Kinase B bands to β-actin bands (Fig 12c). FHM medium was also analyzed as a 
negative control as the cells lysed for rtPCR may have retained some residual medium, which 
would introduce it to the reaction. 
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Figure 12: Presence of Aurora Kinase B and β-actin mRNA in mouse oocytes. A: β-actin reaction product on 
agarose gel. B: Aurora Kinase B reaction product on agarose gel. Lanes are as follows: 3, Cumulus Cells; 4, 10 
MII oocytes; 5, 20 MII oocytes; 6, 10 oocytes 2h post activation; 7, 20 oocytes 2h post activation; 8, 10 oocytes 
5h post activation; 9, 20 oocytes 5h post activation; 10, blank; 11, Negative Control Water. C: Aurora Kinase B 
rtPCR reaction product normalized to β-actin rtPCR product through densitometry analysis. n=10 
oocytes/sample. pa = post-activation. 
 
Quantification of Aurora Kinase B mRNA in Oocytes and Embryos 
 Once rtPCR experiments demonstrated the presence of Aurora Kinase B mRNA in 
mouse oocytes and embryos, q-rtPCR analysis was carried out on oocyte and early embryo 
samples to quantitate changes in the levels of Aurora Kinase B mRNA as development 
progressed. The results of the previously described rtPCR experiments were further 
supported by this analysis as Aurora Kinase B mRNA was again found in all samples analyzed 
(Fig 13A). Ct values obtained for Aurora Kinase B and β-actin were inverted by subtracting 
the raw Ct value from 40, which is the maximum possible Ct value when 40 cycles are run 
(Inverted Ct = 40-Ct). Each individual sample contained 5 oocytes or embryos and there were 
3-6 samples for each developmental stage except the 4-cell stage which had 1 sample. 
Aurora Kinase B mRNA levels stayed at a relatively steady state from germinal vesicle (GV) 
stage through fertilization (1-cell). This is the expected result as there is little to no 
transcription thought to occur in oocytes and early embryos until the zygotic genome is 
activated at about the 2-cell stage. Between the 1-cell and 2-cell stage there was a decrease 
in the Aurora Kinase B mRNA level. This is likely due to the degradation of maternal 
transcripts prior to the synthesis of new transcripts by the zygotic genome. Embryos that 
have developed to the morula or blastocyst stage have relatively little Aurora Kinase B mRNA 
when compared to the earlier developmental stages. At these later stages the pace of the 
embryonic cell cycle slows considerably in blastomeres when compared to earlier stage 
embryos. Therefore, it is not surprising to see a decrease in mRNA levels associated with cell 
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division. Cumulus cells were used as a control to ensure consistency between separate 
analyses using 96-well plates. Cumulus cells were found to have a low level of Aurora Kinase 
B mRNA which was expected as they are known to be not actively proliferating (G0 arrest).  
 
Figure 13: Levels of Aurora Kinase B mRNA and β-actin in mouse oocytes and embryos. A: Inverted Aurora 
Kinase B Ct values, B: Inverted β-actin Ct values. Error bars represent standard error of the mean. 
 
Analysis of Loss of Function of Aurora Kinase B mRNA in Embryos 
 In an attempt to better understand the role of Aurora Kinase B in early mouse 
embryos, one blastomere of a 2-cell embryo was microinjected with a solution of inhibitory 
siRNA constructs specific to Aurora Kinase B. This resulted in each 2-cell embryo containing 
an experimental blastomere devoid of active Aurora Kinase B mRNA and an untreated 
control blastomere. The siRNA solution was a pool of three to five individual constructs, 
resulting in an injection cocktail that was expected to yield high efficiency knockdown of the 
target. To further control for any artifact induced by the microinjection process, a control 
solution consisting of a pool of inert siRNA constructs was microinjected into 1 blastomere of 
2-cell control embryos. A range of concentrations of siRNA solution was used (57 μM, 40μM, 
and 20μM) to determine if there was a difference in knock-down effect with differing 
dosages. Embryos were observed for development and processed for further analysis at 48h 
post-microinjection. This time point gave sufficient time for the siRNA to have an effect. The 
data indicates that the knockdown of Aurora Kinase B was successful in these embryos (Fig 
15) and that the resultant effect observed is similar to the effect of knocking down Aurora 
Kinase B in somatic cells.  
 The embryos injected with either 57 μM or 40μM Aurora Kinase B siRNA solution 
appeared to be severely and similarly affected by the treatment. At 48h post-microinjection 
a majority of embryos subjected to Aurora Kinase B knockdown treatment appeared to be at 
a 3-cell stage (Fig 14a, c, e, and g). Two of the cells within the embryo were approximately 
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equal in size while the third cell was markedly larger. Upon further analysis it was found that 
the large cell of these embryos often contained two distinct nuclei. This data implies that 
there was an attempt at cell division, and karyokinesis progressed while cytokinesis was 
disrupted. Altered progression of cytokinesis is commonly observed in somatic cells in which 
Aurora Kinase B has been inhibited. Control embryos microinjected with the inert siRNA 
solution appeared to have continued a normal pace of development and consisted of many 
cells which were well compacted and in some cases starting to form early blastocysts 
(Fig14b, d, f, and h). 
  
 
Figure 14: Mouse embryos microinjected at the two-cell stage with 40μM Aurora Kinase B targeting siRNA. 
Tub: Tubulin, Act: Actin. Embryos were cultured for 48h post-microinjection before being fixed with PFA and 
processed for immunohistochemistry. DIC imaging shows that the experimental embryos have developed to 
the 3-cell stage (A and C) and have one large multinucleate cell (E and G). One of the control embryos (B) is well 
compacted while the other (D) has entered the early blastocyst stage. Immunohistochemistry reveals that the 
control embryos (F and H) consist of many cells of similar size. Scale bar represents ~40μm. 
 
 
Analysis of these embryo samples by q-rtPCR revealed that Aurora Kinase B mRNA 
was diminished in the experimental treated group when compared to the control 
microinjected group (Fig 15). Calculations were performed on q-rtPCR data as described 
above in the previous section. While the degree of knockdown is not complete, this is to be 
expected given that one of the two blastomeres of the experimental embryo is not treated 
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with siRNA and therefore has a full compliment of Aurora Kinase B mRNA. β-actin levels in 
experimental and control embryos were comparable which suggests that global mRNA 
reduction is not the reason for the decrease in Aurora Kinase B mRNA. 
 
 
Figure 15: Levels of Aurora Kinase B and β-actin mRNA in mouse oocytes and embryos microinjected with 
40μM Aurora Kinase B targeting siRNA. A: Inverted Aurora Kinase B Ct values, B: Inverted β-actin Ct values. n=3, 
each sample contains 5 embryos. Error bars represent standard error of the mean.  
 
 Embryos injected with 20μM Aurora Kinase B siRNA solution appeared to be similarly 
affected, but to a lesser degree than the embryos treated with higher concentrations. 
Experimental embryos and controls from this group both display development well past the 
two-cell stage. However, upon analysis by immunohistochemistry, the experimental 
embryos appeared to have less total cells and were comprised of cells of widely varied sizes 
(Fig 16a and c). Control embryos were comprised of many cells comparable in size to the 
smallest cells found in experimental embryos (Fig 16b and d). This suggests that the 
blastomere microinjected with 20μM Aurora Kinase B siRNA was able to undergo mitosis 
several times, but at a reduced pace. 
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Figure 16: Mouse embryos microinjected at the two-cell stage with 20μM Aurora Kinase B targeting siRNA. 
Tub: Tubulin, Act: Actin. Embryos were cultured for 48h post-microinjection before being fixed with PFA and 
processed for immunohistochemistry. DIC imaging shows that the experimental embryo has developed well 
past the 2-cell stage (A) but, immunohistochemistry analysis (C) reveals that the cells are of varied sizes. The 
control embryo (B) is well compacted and contains many cells. Immunohistochemistry shows that the many 
cells of the control embryo (D) are uniform. Scale bar represents ~40μm. 
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Chapter 3: Aurora Kinase C 
Materials & Methods 
Oocyte/Embryo Collection & Culture 
Methods were as previously described in Chapter 2.  
Immunocytochemistry 
Methods were as previously described in Chapter 2 with the exception that either a 
primary polyclonal anti-AurC antibody (Abgent #AP7000d, 1:100 dilution) or a custom 
produced polyclonal rabbit AurC antibody (Genemed Synthesis, 1:100) was used in these 
analyses.   
Reverse Transcriptase PCR 
Methods were as previously described in Chapter 2. PCR was performed using 
primers specific to Aurora Kinase C and β-actin. Aurora Kinase C primers used were: 
ggctggagtcagagcgttac and tccgggttttcctacctctt, and β-actin primers used were: 
tgttaccaactgggacgaca and ggggtgttgaaggtctcaaa.  
Western Blotting 
 Methods were as previously described in Chapter 2 with the exception that an AurC 
polyclonal (Abgent #AP7000d, 1:400 dilution) was used as the primary antibody.  
Histology 
 Methods were as previously described in Chapter 2 with the exception that a primary 
polyclonal rabbit Aurora Kinase C custom antibody (Genemed Synthesis, 1:100) was used. 
Results 
Localization of Intracellular Aurora Kinase C in Oocytes and Embryos 
 Mouse oocytes and early embryos (1-, 2-, 4-, 8-cell, morula, blastocyst stages) were 
collected and processed using immunocytochemistry methods to assess the presence or 
absence and the localization of Aurora Kinase C. Oocytes ranged from germinal vesicle (GV) 
stage to parthenogenetically activated oocytes cultured to the point of second polar body 
extrusion. Despite employing three different fixation methods, ice cold methanol, 
microtubule stabilizing buffer (MTSB), and 1% paraformaldehyde (PFA), and the use of two 
different Aurora Kinase C polyclonal antibodies, there was no detectable staining specific to 
Aurora Kinase C in any of the oocyte, embryo, or control mouse embryo fibroblast (MEF) 
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samples. The oocyte samples fixed in MTSB and PFA displayed a diffuse punctate staining 
pattern throughout the cytoplasm using both of the Aurora Kinase C antibodies. While this 
pattern was consistent throughout all oocyte samples analyzed, the staining pattern does 
not appear to be concentrated to a specific area of the cell or the spindle itself (Fig 17A). 
Embryos fixed with and probed using the same methods did not appear to exhibit the 
punctate pattern that was obvious in the cytoplasm of oocytes, and did not display Aurora 
Kinase C protein localization to the spindle (Fig 17B). Oocyte and embryo samples fixed in ice 
cold methanol were not able to be analyzed. Much of the structure of the cell was destroyed 
by this harsh fixation technique rendering the samples impossible to analyze. Nuclei and 
microtubules were clearly localized as expected, revealing uniform stained nuclei and 
spindle apparatus respectively. These results validated the immunocytochemistry method 
used. Based upon the previous data showing upregulation of all Aurora Kinase family 
members in cancer cells, a mouse cancer cell line may prove useful as a positive control.  
 
Figure 17: Immunocytochemical localization of Aurora Kinase C (AurC, red), tubulin (Tub, green), and chromatin 
(DNA, blue) in mouse oocytes and early embryos. Samples were fixed in PFA and probed with a custom 
prepared rabbit polyclonal Aurora Kinase C antibody. Panel A shows diffuse punctate red staining is visible 
throughout the cytoplasm of the metaphase II oocyte, but does not appear to be concentrated on the spindle. 
In panel B, Aurora Kinase C protein is not evident in the cytoplasm or on the spindles of blastomeres of the 
cleavage stage embryo. Scale bar represents ~40μm. 
 
Quantification of Intracellular Aurora Kinase B Protein in Oocytes and Embryos 
Mouse oocytes and embryos of various stages were subjected to Western blotting 
concurrently with the immunocytochemistry studies to further validate the presence or 
B A 
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absence of Aurora Kinase C in these samples. Samples were processed as described 
previously in Chapter 2. Several bands were detected when membranes were probed for 
Aurora Kinase C, but were of inappropriate size (Fig 18a). Bands were determined to be 
remnant bovine serum albumin from the oocyte and embryo medium. Extensive washing of 
the cells in PBS/PVP prior to lysis eliminated these bands. No protein bands were detected in 
any stage oocyte or embryo when samples were subjected to the washing procedure. 
Increasing the numbers of cells in the lysate samples (n > 250 oocytes) did not yield positive 
results despite the use of an extremely sensitive chemiluminescent detection method. 
Probing for α/β tubulin protein was successful in these samples, with a band apparent at the 
expected molecular weight (Fig 18b). Therefore, similar to the results from 
immunocytochemistry analysis, there was no Aurora Kinase C protein detected in the lysed 
oocyte or embryo samples. However, it is impossible to conclude that the protein is not 
present in the oocyte and embryo samples due to the lack of a positive control.  Again, the 
inclusion of a mouse cancer cell line would be helpful to validate the sensitivity and 
specificity of the Aurora Kinase C antibodies that were used.  
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Figure 18: Western blot of MII stage mouse oocytes and mouse embryonic fibroblasts probed for A – Aurora 
Kinase C and B – Tubulin. A – A band of inappropriate size is seen at approximately 70kD, but no bands are 
detected at ~33kD, the predicted size for Aurora Kinase C. Blot probed with 1:400 diluted commercially 
available Aurora Kinase C polyclonal primary antibody and 1:10,000 diluted anti-rabbit HRP secondary 
antibody. Mouse Embryonic Fibroblasts (MEF) were used as controls. B – A band of appropriate size is observed 
at approximately 50kD, the predicted size for Tubulin, in both MEF and oocyte lanes. Blot probed with 1:500 
diluted α/β tubulin monoclonal primary antibody and 1:10,000 diluted anti-mouse HRP secondary antibody. 
Mouse Embryonic Fibroblasts (MEF) were used as controls. 
 
Localization of Intracellular Aurora Kinase C Protein in Ovary and Testis Tissue 
 Histology was performed on mouse ovary tissue to determine if Aurora Kinase C was 
present in early oocytes prior to ovulation or in the follicular cells surrounding the oocytes in 
situ. The ovary samples that were analyzed (Fig 19A) showed red fluorescence that was 
indicative of Aurora Kinase C protein localization. The staining pattern was found primarily in 
the follicular cells surrounding the early oocytes, but occasional diffuse staining was 
observed in the oocyte cytoplasm. Signal was detected in the green channel despite the 
absence of a green fluorochrome. The red and green fluorescence appeared to co-localize. 
Accordingly, it was concluded that the ovarian tissue displayed a high level of auto-
fluorescence. Control testis samples (Fig 19B) displayed similar auto-fluorescence in both 
green and red channels further supporting the auto-fluorescence conclusion. Further 
experiments with non-fluorescent detection methods or fluorochromes that do not interact 
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with autofluorescence in these samples may prove more useful for localizing Aurora Kinase C 
in germ cells in situ. 
 
Figure 19: Fixed sections of mouse ovary and testis stained for Aurora Kinase C (red) and chromatin (blue). The 
custom polyclonal Aurora Kinase C rabbit antibody is used. No Green fluorochromes were not used and 
demonstrate a high level of auto-fluorescence in these samples. Scale bar represents ~40μm. 
 
Identification of Aurora Kinase C mRNA in Oocytes and Embryos 
 Given that Aurora Kinase C protein was not able to be detected in any of the samples 
examined via immunocytochemistry or Western blotting, reverse transcription PCR was used 
to determine if there was Aurora Kinase C mRNA transcript present in oocytes and early 
embryos. The presence of the transcript would confirm the possibility of the presence of the 
protein. This would validate further attempts to identify the protein in these samples. As 
expected, Aurora Kinase C transcript was found in all oocyte and embryo samples tested(Fig 
20A). All samples were also analyzed for the presence of β-actin as a control for the assay 
(Fig 20B). Densitometry analysis was used to normalize Aurora Kinase C bands to β-actin 
bands (Fig 20C). FHM medium was also analyzed as a negative control as some of it may 
have been introduced to the reactions with the cells. 
B A 
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Figure 20: Presence of Aurora Kinase C and β-actin mRNA in mouse oocytes. A: β-actin reaction product on 
agarose gel. B: Aurora Kinase C reaction product on agarose gel. Lanes are as follows: 3, Cumulus Cells; 4, 10 
MII oocytes; 5, 20 MII oocytes; 6, 10 oocytes 2h post activation; 7, 20 oocytes 2h post activation; 8, 10 oocytes 
5h post activation; 9, 20 oocytes 5h post activation; 10, blank; 11, Negative Control Water. C: Aurora Kinase C 
rtPCR reaction product normalized to β-actin rtPCR product through densitometry analysis. n=10 
oocytes/sample. 
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Chapter 4: Simultaneous Inhibition of Multiple Aurora Kinases 
Materials and Methods 
Oocyte Collection & Culture 
Methods were as previously described in Chapter 2.  
Hesperadin Treatment 
 Oocytes were harvested at telophase I or metaphase II stages and treated with 
250nM Hesperadin, an inhibitor of all Aurora Kinase proteins (Hauf et al., 2003), in the 
culture medium. Control samples with no treatment or treatment with an inert compound 
were cultured simultaneously with the experimental group. Telophase I oocytes were 
collected from ovaries 10h post-hCG injection and cultured for 6h and then activated with 
10mM SrCl2 in the culture medium. Oocytes collected and treated at the metaphase II stage 
(16h post-eCG injection) were immediately cultured with 10mM SrCl2 in the culture medium. 
Samples were then fixed in 1% paraformaldehyde and 0.15% triton X-100 (see Appendix A) 
for 30m at 37°C and processed for immunofluorescence as described below. Oocytes 
collected at the telophase I stage were fixed at 6h and 10h post-harvest. Oocytes collected 
at the metaphase II stage were fixed at 4h post-harvest. 
ZM447439 Treatment 
 Oocytes were harvested from stimulated ovaries at the GV or metaphase II stages 
and treated with 20μM ZM447439 (Tocris bioscience #154252) dissolved in DMSO in the 
culture medium. At this concentration ZM447439 is reported to inhibit Aurora Kinase B, but 
not Aurora Kinase A (Mortlock et al., 2007). The effect upon Aurora Kinase C is unknown. 
Control samples with no treatment or DMSO only treatment were cultured simultaneously 
with the experimental group. GV samples were cultured for 20h post-harvest. MII samples 
were activated with 10mM SrCl2 in the culture medium and matured for 4h post-harvest. 
Samples were then fixed and processed for immunofluorescence as described below.  
Immunocytochemistry 
Mouse oocyte and embryo samples were fixed in 1% paraformaldehyde and 0.15% 
triton X-100 for 30m at 37°C. Samples were subsequently stored at 4°C in a blocking solution 
(see appendix A) until being further processed. Immunolocalization was performed using 
antibodies for Aurora Kinase B (AurB), Histone H3 (phosphorylated on serine 10, phospho 
H3), and microtubules (Tub). Chromatin was labeled using Hoechst 33258 (Molecular Probes 
#H-1398) as described previously. Aurora Kinase B was detected with primary polyclonal 
 
 
42 
 
anti-AurB antibody (Abcam #ab2254, 1:500 dilution). Phosphorylated Histone H3 was 
detected with a polyclonal rabbit anti-Ser10 phospho H3 antibody (Upstate #06-570, 1:200 
dilution). The primary probes, AurB or phospho H3, were followed by a secondary Alexa 
fluor 594 labeled goat anti-rabbit antibody (Invitrogen #A11072, 1:400 dilution). A mixture of 
primary monoclonal anti-α-tubulin and anti-β-tubulin antibodies (Sigma-Aldrich Co #T-9026 
and #T-4026 respectively, 1:1000 dilution) followed by a secondary Alexa fluor 488 labeled 
goat anti-mouse antibody (Invitrogen #A21121, 1:400 dilution) was used to label 
microtubules. F-actin was labeled using of 8U/mL rhodamine phalloidin (Molecular Probes 
#R-415). Labeled eggs were then mounted onto slides and analyzed using a Zeiss Axiovert 
200M inverted microscope coupled to a Roper CoolSnapFx high resolution CCD camera. 
Images were captured and rendered in real time using Axiovision software.  
 
Results 
Hesperadin Treatment 
 The compound Hesperadin is known to inhibit the activity of all three of the Aurora 
Kinase proteins (Hauf et al., 2003). Mouse oocytes were treated with Hesperadin to 
determine the extent and nature of functional loss of the Aurora Kinase proteins as oocytes 
underwent the process of meiosis. Phosphorylation status of Histone H3 on Serine 10 was 
monitored as an indicator of Aurora Kinase B activity. Although roles for individual Aurora 
Kinases were not distinguishable, the Hesperadin studies did reveal the broad impact of 
Aurora Kinase inhibition during progression of meiosis in mouse oocytes. 
 Metaphase II (MII) oocytes were treated with Hesperadin to ascertain the effect of 
Aurora Kinase inhibition in the completion of M-phase. Analysis of the treated and control 
samples revealed that Hesperadin treatment had little effect on these oocytes. At 4h post-
treatment and SrCl2 activation the Hesperadin treated MII oocytes appeared to proceed 
through M -phase without delay or defect. The extrusion of the second polar body occurred 
on time (Fig 21A-C) and the chromosomes appeared to segregate normally (Fig 21G-H). 
Histone H3 phosphorylation was not detected in any of the samples analyzed most likely due 
to the stage of the cell cycle (Fig 21D-F). Analysis of the oocytes gross morphology and 
meiosis I completion through immunocytochemistry did not reveal any differences between 
experimental and control oocytes. This suggested that either the Aurora Kinase proteins did 
not have a role in the completion of meiosis in mouse oocytes or that the timing of the 
treatment did not allow it to have an effect. Given that at the MII stage the spindle is already 
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assembled and the chromosomes have aligned, forming the metaphase plate, it is possible 
that the Hesperadin compound was unable to inhibit the Aurora Kinase proteins from 
participating in the completion of M-phase of the cell cycle.  
 
Figure 21: Mouse oocytes treated with Hesperadin (Hesp) at the MII stage and controls fixed at 4h post-
treatment. A, D, G – Controls cultured in medium. B, E, H – Controls cultured in inert compound and vehicle in 
medium. C, F, I – Hesperadin treated samples. There is no discernable difference between control oocytes 
(untreated), inert Hesperadin analog treated oocytes, and Hesperadin treated oocytes in gross morphology (A-
C) or protein staining patterns (phospho H3 D-F and Tubulins (Tub)/chromatin (DNA) G-H). Scale bar represents 
~40μm. 
 
In order to determine if the lack of observable aberrant phenotype in the MII 
Hesperadin treated oocytes was due to the timing of the treatment in the cell cycle, 
telophase I (TI) stage oocytes were treated with Hesperadin. This would allow the compound 
to be present earlier when the meiosis II spindle was assembled. Analysis of TI oocytes 
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revealed that Hesperadin treatment resulted in aberrant completion of meiosis. At 6h post-
treatment the oocytes appeared morphologically normal when observed by vital phase 
contrast microscopy (Fig 22C). However, immunocytochemical analysis revealed that the MII 
spindle was abnormally shaped and lacked any distinct poles (Fig 22I). The chromatin was 
condensed and associated with the mictotubules, but not in an organized fashion. Histone 
H3 was not phosphorylated which indicated inhibition of Aurora Kinase B (Fig 22F). Control 
oocytes displayed a normal MII morphology with bi-polar spindles, metaphase plates, and 
phosphorylated of Histone H3 (Fig 22A-B, D-E, G-H).  
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 Figure 22: Mouse oocytes treated with Hesperadin (Hesp) at the TI stage and controls fixed at 6h post-
treatment. A, D, G – Controls cultured in medium. B, E, H – Controls cultured in inert compound and vehicle in 
medium. C, F, I – Hesperadin treated samples. Control oocytes and inert Hesperadin analog treated oocytes 
display a typical MII stage gross morphology (A & B) with bi-polar spindles and chromatin aligned on a 
metaphase plate (G & H). Serine 10 of Histone H3 is phosphorylated (D & E). Hesperadin treated oocytes 
display an abnormal phenotype despite appearing to have a similar gross morphology to control oocytes (C). 
Microtubules are disorganized without discernable spindle poles, chromatin is not aligned (I), and there is 
absence of Serine 10 phosphorylation on Histone H3 (F). Scale bar represents ~40μm. 
 
Oocytes that were exposed to Hesperadin at the TI stage were further affected at 
10h post-treatment. Non-treated SrCl2 activated control oocytes completed M-phase as 
revealed by extruding a second polar body. Although experimental and control oocytes were 
not phenotypically distinguished from each other when viewed by bright field microscopy 
(Fig 23A-C), immunocytochemistry exposed severe defects in meiosis completion in 
Hesperadin treated oocytes. Polymerized microtubules were arranged into a complex 
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network throughout the cytoplasm rather than forming a midbody as was observed in 
control oocytes (Fig 23I). There was no evidence of extrusion of the second polar body and 
the chromatin appeared to be in one large cluster suggesting that neither spindle formation 
nor chromosome alignment has occurred. Control oocytes displayed a normal interphase 
morphology with elongated, disintegrating spindles and de-condensed chromatin (Fig 23G-
H). Histone H3 was not phosphorylated on Serine 10 in experimental or control samples at 
this time point most likely due to the stage of cell cycle (Fig 23D-F).  
 
 Figure 23: Mouse oocytes treated with Hesperadin (Hesp) at the TI stage and controls fixed at 10h 
post-treatment. A, D, G – Controls cultured in medium. B, E, H – Controls cultured in inert compound and 
vehicle in medium. C, F, I – Hesperadin treated samples. Control oocytes (untreated) and inert Hesperadin 
analog treated oocytes display a typical interphase morphology. Whereas, hesperadin treated oocytes display 
an abnormal phenotype. Scale bar represents ~40μm. 
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ZM447439 Treatment 
 The compound ZM447439 (ZM) is known to inhibit Aurora Kinase B, but not thought 
to affect Aurora Kinase A when used at 20μM concentration (Mortlock et al., 2007). The 
effect upon Aurora Kinase C at this concentration is not known. Experiments conducted with 
ZM allow the further dissection of the role of Aurora Kinase proteins in the completion of 
meiosis in mouse oocytes. Staining for tubulin, actin, and chromatin was chosen because it 
allowed for the study of spindle formation, chromatin separation, and polar body extrusion 
in the oocytes.  
 Metaphase II (MII) oocytes were treated with 20μM ZM compound to elucidate the 
role of Aurora Kinases B (and/or C) in the completion of meiosis after fertilization or 
activation. Analysis of the treated samples at 4h post-activation and treatment revealed 
oocytes that had not properly completed meiosis (Fig 24B). It was apparent that the tubulin 
spindle formed prior to the MII stage had been disrupted and tubulin protein was now 
organized in to a complex matrix throughout the cytoplasm. There was no evidence of 
extrusion of polar body II and the chromatin appeared to be concentrated in one area. This 
indicated that ZM was able to disrupt an assembled spindle and that both karyokinesis and 
cytokinesis had failed in the treated oocytes. Control oocytes completed meiosis as normal 
(Fig 24A). Polar body II was extruded along with approximately half of the chromatin. The 
remnant of the tubulin spindle was elongated and had formed a midbody between the 
oocyte and second polar body.  
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Figure 24: Mouse oocytes activated and treated with ZM447439 at the MII stage and controls treated with 
DMSO fixed at 4h post-treatment and activation. A – Control oocytes and display a typical interphase 
morphology. B – ZM447439 treated oocytes display an abnormal phenotype. Scale bar represents ~40μm. 
 
 Germinal vesicle (GV) stage oocytes were also treated with 20μM ZM compound to 
determine the role of Aurora Kinase B and/or C in the earliest stages of meiosis in mouse 
oocytes. At 20h post-treatment the ZM treated GV oocytes appeared to have arrested and 
displayed a morphology much like that of a newly harvested GV stage oocyte (Fig 25B). 
There was no evidence of germinal vesicle break down or DNA condensation. Tubulin was 
distributed throughout the cytoplasm without any indication of spindle formation. Control 
oocytes treated with DMSO in the medium and cultured for 20h post-treatment show a 
typical metaphase II morphology (Fig 25A). The tubulin is organized into a bi-polar spindle 
and all chromatin is condensed and aligned at the metaphase plate.  The first polar body 
extruded successfully along with chromatin. The control oocytes appear to have progressed 
normally through M-phase to the MII checkpoint and arrested. 
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Figure 25: Mouse oocytes treated with ZM447439 at the GV stage and control treated with DMSO fixed at 20h 
post-treatment. A – Control oocytes and display a typical MII morphology. Tubulin has formed a bi-polar 
spindle and the chromatin is condensed and aligned on the metaphase plate. B – ZM447439 treated oocytes 
display an abnormal phenotype that appears to be much like a GV oocyte without any progression into meiosis. 
Scale bar represents ~40μm. 
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Chapter 5: Discussion and Conclusions  
The purpose of these studies was to elucidate the localization and function of several 
of the Aurora Kinase family proteins in during late oogenesis and early embryonic 
development in the mouse. An understanding of the roles of these key regulatory kinases 
would be useful for several in vitro applications including maturation of oocytes, culture of 
early embryos, and oocytes manipulated for somatic cell nuclear transfer. Results of these 
studies have established that the localization pattern of Aurora Kinase B in mouse oocytes 
does not mimic the pattern observed in somatic cells. For example, Aurora Kinase B was not 
present in the oocytes or embryos until the 4-cell embryos cleaved to 8-cells. The timing of 
the appearance coincides with the activation of the embryonic genome in mouse embryos. 
In contrast, the localization and expression of Aurora Kinase C proved more difficult to 
uncover. The apparent low abundance of Aurora Kinase C in somatic cells proved to be a 
major obstacle for studies in mouse oocytes and embryos. However, a functional role for 
Aurora Kinase proteins B (and/or C) was demonstrated in mouse oocytes and embryos. The 
inhibition of Aurora Kinase B mRNA with specific targeting siRNAs revealed a role for the 
gene product in the first cleavage events of embryos. Broad, simultaneous drug inhibition of 
Aurora Kinases also demonstrated the functional requirement of the Aurora Kinase family 
during late oogenesis. Tubulin assembly, chromatin organization, and cytokinesis were all 
affected leading to failure of proper cell division. When considered as a whole, this work 
reveals new information about the Aurora Kinase family in mouse oocytes and embryos. In 
particular, the absence of Aurora Kinase B in meiosis II oocytes and the functional roles of 
Aurora Kinase B and C in oogenesis and early embryogenesis are both valuable pieces of 
information. Understanding the endogenous expression patterns of the Aurora Kinase 
mRNAs and proteins in mouse oocytes and early embryos elucidates important controls of 
the cell cycle in these cells. Further knowledge of the properties of proteins in control of the 
cell cycle in oocytes and embryos will allow for future work on a wide variety of topics such 
as somatic cell nuclear transfer, assisted reproductive techniques, and enhanced agricultural 
breeding.  
Aurora Kinase B 
Protein Expression and Localization 
The experimental studies designed to illustrate the characteristics of Aurora Kinase B 
showed unexpected results, but these results were confirmed through the use of several 
different techniques. The working hypothesis was that Aurora Kinase B in mouse oocytes 
and embryos would function much like what is observed in somatic cells. This hypothesis 
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was first challenged when immunocytochemical analysis showed that Aurora Kinase B was 
not found to be localized to the meiotic spindle in metaphase II stage mouse oocytes despite 
clear evidence of control staining of mouse embryonic fibroblasts that displayed typical 
Aurora Kinase B localization. Aurora Kinase B protein was found co-localized with 
centromeres at metaphase, remained at the spindle midzone during anaphase and early 
telophase, and was on the narrowing midbody during late telophase. These findings were 
further supported by analysis of protein expression using Western blotting methods. The 
apparent absence of Aurora Kinase B protein in mouse oocyte samples demonstrated that 
not only is the protein not localized, it is not detectable based on the high resolution 
methods used. This also showed that the diffuse punctate staining pattern observed in the 
mouse oocytes is not likely Aurora Kinase B given that it is not detected in any quantity or 
form on Western blots. 
Aurora Kinase B protein was not detected in early embryo samples. From the 1-cell 
fertilized stage to approximately the 4-cell stage Aurora Kinase B protein was undetectable. 
As the 4-cell embryos cleaved to the 8-cell stage Aurora Kinase B appeared and was localized 
on the midbody between the dividing cells as is seen in the control mouse embryonic 
fibroblast cell samples. Given the timing of appearance of Aurora Kinase B protein, one 
explanation is that the protein is produced as a result of the activation of the zygotic 
genome. In mice, zygotic gene activation is initiated at approximately the 2-cell stage. Prior 
to activation, it is generally accepted that all of the proteins used by the embryo are of 
maternal origin since the embryonic genome is silent (Bettegowda & Smith, 2007). The 
appearance of Aurora Kinase B protein post-zygotic genome activation indicates that the 
protein is not necessary for proper cell cycling in the early cleavage stage embryo.  
This data is contrary to what has been previously reported for other chromosome 
passenger complex proteins in mouse oocytes and early embryos. Survivin protein, another 
member of the chromosomal passenger complex, has been found in mouse oocytes 
currently undergoing meiosis (Sun et al., 2009). Localization of survivin protein in mouse 
oocytes was found to be similar to the pattern observed in somatic cells. Survivin was 
observed to be co-localized with centromeres during germinal vesicle breakdown in early 
meiosis, and then remained at the spindle midzone as the chromatin migrated to the poles 
of the spindle. Finally, survivin protein was observed at the spindle midbody just before the 
completion of cytokinesis, or excision, as is observed in somatic cells (Sun et al., 2009). 
Aurora Kinse B has also been found present and localized in mouse oocytes, but only in 
meiosis I stage oocytes (Shuda et al., 2009). These data, along with the Aurora Kinase B 
immunocytochemistry data discussed above above, indicate that it is not the entirety of the 
chromosomal passenger complex that is absent in mouse oocytes, but that the complex 
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consists of different components in these cells. Other members of the chromosomal 
passenger complex have not been studied in mouse oocytes, and future analyses of proteins 
such as INCENP and Borealin may provide further insight into the makeup and function of 
the chromosomal passenger complex in mouse oocytes performing meiosis.  
mRNA Expression and Relative Quantitation 
Although this work established that Aurora Kinase B protein is not detectable in the 
mouse oocyte or the earliest embryos through complimentary immunohistochemistry and 
Western blotting analysis, further studies were warranted to determine if Aurora Kinase B 
mRNA was present, but not translated, or if it was also not expressed. Reverse transcriptase 
PCR and quantitative-rtPCR were both employed to uncover the details of Aurora Kinase B 
mRNA in mouse oocytes and embryos. Both approaches showed that Aurora Kinase B mRNA 
is indeed present in both oocytes and embryos. This suggests that Aurora Kinase B protein is 
absent due to a transcriptional control rather than absence of transcript. Details of the 
mechanism and proteins associated with this regulation are currently unknown and further 
studies with inhibitors of transcription may be useful to address this question.  
When compared to β-actin, Aurora Kinase B mRNA is found in very low abundance in 
oocytes and embryos assayed. Aurora Kinase B mRNA levels remain unchanged form GV 
stage through fertilization to the 1-cell stage. There is an evident decrease in Aurora Kinase B 
mRNA at the 2-cell stage which is most likely attributed to the degradation of maternal 
transcripts. This pattern of mRNA quantification is commonly observed in mouse oocytes 
subjected to qrt-PCR analysis. SEBOX, a regulator of transcription, is observed in a similar 
expression level outline. A slight decrease of SEBOX mRNA is observed between the 1- and 2-
cell stages and then the mRNA becomes nearly undetectable at the 4-cell stage (Kim et al., 
2008). Peroxiredoxin II mRNA also follows a comparable expression profile. The 
peroxiredoxin family has been found to play roles in eliminating reactive oxygen species, 
intracellular signal transduction, and control of cell proliferation (Kang et al., 1998). In mouse 
oocytes and early embryos peroxiredoxin II mRNA is found present fro the germinal vesicle 
stage through the 2-cell stage. From the 4-cell stage forward the mRNA is not able to be 
detected (Wang et al., 2010).  
Aurora Kinase B transcript levels recover at the morula and blastocyst stages after 
the activation of the embryonic genome. β-actin transcript levels mimic Aurora Kinase B in 
the oocyte and early embryo stages, but after the activation of the zygotic genome there is a 
marked increase in level of β-actin mRNA in the embryos. The comparative low levels of 
Aurora Kinase B transcript in the later stage embryos may be due to the slowing of the cell 
cycle in the embryonic cells as well as the tendency toward asynchrony of the cell cycles in 
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the many embryonic cells. There are other reports in the literature of mitotic cell cycle 
control proteins being upregulated after the activation of the zygotic genome, namely 
retinoblastoma. This protein controls the mitotic cell cycle by inhibiting the cell from 
progressing from G1 to S phase. The mRNA transcript of this gene is found in oocytes, 
decreases at zygotic genome activation, and is again propagated from the 8-cell stage 
onward (Xie et al., 2005). This closely mimics the pattern observed for Aurora Kinase B 
mRNA in mouse oocytes and early embryos. 
Loss of Function 
The results observed in the mouse embryos treated with various concentrations of 
Aurora Kinase B targeting siRNAs appeared in a dose dependant manner. Blastomeres 
subjected to higher concentrations of Aurora Kinase B inhibitory RNAi (57μM and 40μM) 
appeared to have immediate difficulty completing cytokinesis. In addition, the entire embryo 
ceased development shortly after one cell division. Reducing the concentration of the RNAi 
solution to 20μM mitigated the resultant effects, but did not completely suppress the 
phenotype. Embryos were able to continue development and perform compaction and early 
blastocyst formation. While the experimental embryos progressed through several 
developmental stages, the cells comprising these embryos were not comparable to control 
embryos. Similarly to the embryos treated with more concentrate RNAi solution, cytokinesis 
defects were evident.  
Embryos depleted of Aurora Kinase B mRNA through the use of RNAi knockdown 
showed striking differences when compared to control embryos. Interestingly, the 
experimental embryos displaying an abnormal phenotype were at developmental stages 
prior to when Aurora Kinase B protein is detected. Given that in these stages of embryos 
there is no detectable Aurora Kinase B protein, these results suggest that the observed 
effect may be due to an off-target effect of the siRNA, a function of the Aurora Kinase B 
mRNA that is lost upon its degradation, or that Aurora Kinase B protein is present and unable 
to be detected with the methods employed. The likelihood of an off-target effect of the 
siRNA is small. In particular, the quantification of β-actin mRNA in the treated and control 
embryos did not show any differences. While this is one transcript, amongst thousands of 
mRNAs, in the mouse embryo, its stable quantification between experimental and control 
embryos demonstrates that there is no global decrease in the mRNA quantity in the treated 
embryos. The siRNA used was a pool of 3 constructs commercially designed to specifically 
target Aurora Kinase B. The use of more than one construct at the same time diminishes the 
outcome of a possible off-target effect of one of the constructs. Microarray analysis of the 
treated and control embryos would allow for the comparison of many genes to better 
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determine the specificity of the siRNA pool used. If Aurora Kinase B protein is present in the 
embryos, but not detected, the use of different antibodies, alteration of staining technique, 
or more sensitive detection methods may reveal the presence and localization of the 
protein. 
It is well known that RNAs can have an additional function as well as their role in 
gene expression. It has been previously shown that coding RNAs have structural functions in 
the assembly of the microtubule spindle and chromatin organization in oocytes and embryos 
of Spisula (surf clam), Xenopus, and Drosophila. Spisula embryos were found to have 
centrosome-associated RNAs which are thought to participate in the assembly of the mitotic 
sprindle. In Xenopus oocytes microtubule-associated RNAs were found and inhibition of 
translation did not alter their localization (Kloc, 2009). If the Aurora Kinase B mRNA is playing 
a role similar to any of these examples, its depletion via the siRNA constructs may yield a 
phenotype much like what was observed. 
 In addition to the activities of coding RNAs, many RNAs that were previously thought 
to be non-functional or untranslated, are now being found to be a regulatory mechanism 
(Keene, 2010). There is evidence that there may be specific microRNAs (miRNAs) in 
pluripotent cells, such as those in an embryo, that are not found in differentiated cells. Many 
of these miRNAs have been implicated in differentiation of different cell types and the 
proliferation of cells from the pluripotent original cell (Foshay and Gallicano, 2007). If the 
siRNA pool used to target Aurora Kinase B had an off-target effect upon one of these 
miRNAs it would not be evident in somatic cells, but would cause distinct defects in the 
development of embryos. This is a possible cause for the phenotype observed in cells 
microinjected with Aurora Kinase B targeting siRNA. To further investigate this prospect, 
microarray analysis of miRNAs in the embryo could be conducted. 
While this preliminary data suggests that Aurora Kinase B may play a pivotal role in 
the cell division of early mouse embryos, there are several deficiencies which must be 
remedied before conclusions may be drawn. It is assumed that the larger cells observed in 
the experimental microinjected embryos are the blastomeres that were treated with Aurora 
Kinase B siRNA solution. Without a tracking system for the microinjected cell, it is impossible 
to know which cells are derived from treated or untreated blastomeres. Once this obstacle is 
remedied, further studies can be conducted and significant sample numbers can be collected 
for each category at several time points.  
Aurora Kinase C 
The studies focused upon Aurora Kinase C protein proved far less fruitful than those 
concentrated on Aurora Kinase B. Few conclusions can be drawn from the many experiments 
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performed due to the fact that a reliable positive control was unable to be found. Somatic 
cells have a very low level of Aurora Kinase C making them a poor positive control. The low 
levels of the protein make it difficult to reliably detect with a variety of methods. Given the 
known upregulation of all Aurora Kinase proteins in many types of tumors, it may prove 
useful to investigate them as a positive control. A mouse tumor cell line would be ideal to 
ensure that the probes used detect the protein in the species being studied. Given the 
interesting results found when studying Aurora Kinase B in mouse oocytes and embryos, 
Aurora Kinase C investigations may unveil exciting new information about cell cycle 
mechanisms and controls in these cells. The absence of Aurora Kinase B in meiosis II oocytes 
and early embryos along with the successful progression of the cell cycle in these cells may 
indicate that another protein, such as Aurora Kinase C, could be compensating. Aurora 
Kinase C has been shown to be able to compensate for the loss of Aurora Kinase B in HeLa 
cells (Sasai et al., 2004). It is possible that this scenario is occurring in oocytes and early 
embryos as well. Additional antibodies targeted to different regions of the protein or 
transgenic animals with fluorescently tagged Aurora Kinase C protein may help to unveil the 
properties of this protein in mouse oocytes and early embryos.  
Inhibition of Multiple Aurora Kinases 
In order to further study the effects of the loss of the Aurora Kinase proteins in 
mouse oocytes chemical compounds were used to simultaneously inhibit multiple members 
of the family. Oocytes treated with Hesperadin or ZM447439 showed marked defects 
catastrophic to development.  While it is impossible to know exactly which of the Aurora 
Kinase family members is responsible for the observed effects, it is possible to compare the 
results with previous studies targeting a single protein. Yao et al. (2004) showed that 
inhibition of Aurora Kinase A protein in mouse oocytes through the use of monoclonal 
antibodies produced a variety spindle defects. Cytokinesis defects were not noted in these 
oocytes. When Hesperadin was used with telophase I oocytes spindle defects were observed 
as well as the failure of cytokinesis. Clearly, a protein in addition to Aurora Kinase A is being 
affected in these oocytes. The results of Shuda et al. show that Aurora Kinase B protein is 
involved in meiosis I, but not meiosis II (Shuda et al., 2004). Therefore, the defect observed 
with broad Aurora Kinase inhibitors in meiosis II can not be attributed to Aurora Kinase B 
inhibition. These previous data, coupled with the findings of Shuda et al. and our own 
results, indicating that Aurora Kinase B protein is not present during meiosis II, one can 
theorize that Aurora Kinase C may be the inhibited protein.  
Similar effects were observed in oocytes that were treated with ZM447439, which is 
specific to Aurora Kinase B and perhaps affects Aurora Kinase C. Aurora Kinase A is not 
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affected by this inhibitor (Mortlock et al., 2007). The meiotic spindle failed to organize in 
these oocytes. Even with ample time to develop, meiosis did not continue in these oocytes 
and ultimately there was no cytokinesis or karyokinesis evident. Given that Aurora Kinase A 
is not affected in these studies, the spindle assembly failure must be attributed to another 
inhibited protein. It has been previously shown that Aurora Kinase C protein is responsible 
for proper chromatin segregation and cytokinesis during meiosis in developing sperm cells 
(Kimmins et al., 2007). It is possible, although not yet proven, that Aurora Kinase C may play 
this same role during meiosis in developing oocytes. The data of Shuda et al. explain that 
Aurora Kinase B inhibition may be the responsible for the observed phenotype. 
Unfortunately, Shuda et al. were not able to confirm the presence of Aurora Kinase B with 
immunocytochemistry or Western blotting, but rather relied upon the microinjection of a 
fluorescently tagged mRNA to indicate protein localization (Shuda et al. 20079). Given the 
difficulties had identifying the native protein with several methods, it must be considered 
that the native protein may not be present in the oocytes. The microinjected fluorescently 
tagged mRNA could have been translated in the treated oocytes, giving the impression that 
the protein localized to the spindle. In summary, the failure of the oocytes treated with 
ZM447439 to enter GVBD and progress through M phase may be due to the inhibition of 
Aurora Kinase B or C protein.  
Conclusions 
The results of these studies suggest a possible role for Aurora Kinase C in the 
maturation of mouse oocytes and early embryo development, and illustrate the importance 
of future studies of this protein during oogenesis. Aurora Kinase C may prove to be a very 
important player in the orchestration of a successful cell cycle in mouse oocytes and early 
embryos given its previously demonstrated ability to compensate for the lack Aurora Kinase 
B (Sasai et al., 2004) and its role in spermatogenesis (Kimmins et al., 2007). This also 
demonstrates the importance of an Aurora Kinase C positive control. Our data show that 
there are distinct differences in the members of the chromosomal passenger complex in 
mouse oocytes and mouse embryonic fibroblast somatic cells. These findings represent a 
significant advancement in the understanding of cell cycle control in developing oocytes and 
the differences in meiosis and mitosis. This insight becomes especially important when 
somatic cells and oocytes are combined through the process of somatic cell nuclear transfer. 
Typically, a somatic nucleus is inserted into a cytoplast produced from a meiosis II oocyte. As 
this reconstructed embryo divides the somatic chromatin must reprogram to develop the 
embryonic organism. In somatic cells the chromosomal passenger complex includes Aurora 
Kinase B protein, but the embryonic chromosomal passenger complex in oocytes at this 
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stage does not. This reprogramming may not occur efficiently and therefore impact the 
ability of the developing embryo to properly undergo cell division. Future experiments 
including the study of the chromosomal passenger complex in somatic cell nuclear transfer 
reconstructed embryos will further elucidate the members and status of this complex in 
manipulated embryos.  
Further experimentation to discover the role of Aurora Kinase B mRNA in early 
embryo samples is also an interesting topic. It was shown via several different methods that 
Aurora Kinase B protein is absent in embryos prior to zygotic genome activation. Despite this 
finding, the depletion of Aurora Kinase B mRNA in one blastomere of a 2-cell embryo 
produced a profound effect on early embryos. Future experiments to uncover the finctions 
and interactions of this mRNA may also yield important information about the control of the 
cell cycle of early embryos. Microarray analysis of the Aurora Kinase B mRNA depleted 
embryos would allow for the simultaneous study of many transcripts. This may show 
transcripts that the siRNA is targeting as well as transcripts that are affected by the loss of 
Aurora Kinase B mRNA. These proposed studies would expand upon the results of the 
current investigations as well as increase overall understanding of cell cycle mechanisms and 
control in mouse oocytes and embryos.  
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Appendix A 
Solutions 
Stabilization Buffer (SB) 
Composition: 
100mM PIPES 
5mM MgCl2  
2.5.mM EGTA 
 
Preparation: 10mL 1x SB 
 0.3024g PIPES (Sigma #P-6757, MW 302.4) 
 0.0102g MgCl2·6H2O (Sigma #M-2393, MW 203.3) 
 0.0095g EGTA (Sigma #E-4378, MW 380.4)  
 
Microtubule Stabilization Buffer – Extraction Fixative (MTSB-XF) 
This fixative is designed to diminish changes in microtubule structure as a result of fixation 
while effectively fixing and extracting the cells.  
Composition: 
100mM PIPES 
5mM MgCl2  
2.mM EGTA 
1mM DTT (Sigma #D-0632, FW 154.2) 
1μM Taxol 
0.01% Aprotinin 
50% Deuterium Oxide 
3.7% Formaldehyde 
0.1% Triton X-100 
 
Preparation: 1mL MTSB-XF 
 200μL 5x Stabilization buffer 
 50μL Aprotinin 0.2%  
 50μL DTT 20mM  
 50μL Taxol 20μM 
 500μL Deuterium oxide 99.9%  
 50μL Triton X-100 2% 
 100μL Formaldehyde 37% 
Store at 4°C. Solution expires 3 weeks from date of preparation. 
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Immunocytochemistry Blocking Solution  
 
Composition: 
0.2% Sodium azide 
1% (w/v) Bovine serum albumin, Fraction V (BSA, Sigma #A-6793) 
0.2% (w/v) Powdered milk (non-fat dry milk, Carnation brand) 
2% (v/v) Normal goat serum (heat-inactivated, Sigma #S-6898) 
0.1M Glycine (Sigma #G-7126, MW 75.1) 
0.01% Triton X-100 
 
Preparation: 50mL Immunocytochemistry Blocking Solution 
49mL Dulbeccos’a Phosphate-Buffered Saline 
0.098g Sodium azide 
 0.1g Powdered milk  
 1mL Normal goat serum 
 0.5g Bovine serum albumin fraction V 
 500μL Deuterium oxide 99.9%  
 50μL Triton X-100 2% 
 100μL Formaldehyde 37% 
Store at 4°C. Solution expires 3 weeks from date of preparation. 
 
Western Blotting Blocking Solution  
 
Tris-Buffered Saline (TBS, 10x) 
Composition: 
250mL 1M Tris-HCl pH 8.0 (Sigma #T5941) 
80g NaCl (Sigma #9625) 
 Dilute to 1x with distilled H2O  
 
Tris-Buffered Saline with 0.1% Tween-20 (TBS-T, 1x) 
Composition: 
100mL 1x TBS 
100μL Tween-20 (Fisher #BP337) 
 
Western Blotting Blocking Solution 
Composition: 
50mL TBS-T 
2.5g Powdered milk 
Store at 4°C. 
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FHM HEPES Buffered Medium with Phenol Red and amino acids (Millipore #MR-024-D) 
Working pH range 7.2 - 7.4  
 
Composition:  (mg/L)  
 
Inorganic Salts      
CaCl2-2H2O  251.00  
KCL   186.00  
KH2PO4  47.60  
MgSO4 (anhyd)  24.10  
MgSO4-7H2O  ---  
NaCl   5550.00  
NaHCO3  336.00  
 
Amino Acids      
L-Glutamine   146.00  
 
Other Components     
BSA    1000.00  
EDTA    3.80  
D-Glucose   36.00  
HEPES    4760.00  
Hyaluronidase  ---  
Ca Lactate   ---  
Na Lactate 60% (ml/L)  1.86  
Lactate NaSalt (ml/L)  ---  
Sodium Pyruvate  22.00  
Phenol Red   10.00  
Antibiotics     
Penicillin G NaSalt (u/L)  100,000.00  
Streptomycin Sulfate  50.00  
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KSOM Medium with amino acids (Millipore #MR-106-D) 
Working pH range 7.2 - 7.4  
 
Composition: (mg/L) 
 
Inorganic Salts      
CaCl2-2H2O 250.00  
KCL   186.38  
KH2PO4    47.99  
MgSO4   ---  
MgSO4 7H2O  49.30  
NaCl   5551.80  
NaHCO3  2100.25  
 
Other Components      
EDTA    3.72  
D-Glucose   36.03  
Sodium Lactate   1121.00  
Lactate NaSalt (ml/L) ---  
Sodium Pyruvate  22.00  
BSA    1000.00  
Phenol Red   ----  
 
 
Amino Acids      
L-Arginine   63.20  
L-Cystine   12.02  
L-Cystine-2HCL   ---  
L-Glutamine   146.15  
Glycine   3.75  
L-Histidine   ---   
L-Histidine.HCl.H2O  20.96  
L-Isoleucine   26.23 
L-Leucine   26.24 
L-Lysine   ---  
L-Lysine.HCl   36.52 
L-Methionine   7.46  
L-Phenylalanine  16.52   
 
L-Serine   5.26  
L-Threonine   23.82 
L-Tryptophan   5.11 
L-Tyrosine   18.12 
L-Tyrosine NaH2O  ---  
L-Valine   23.42 
L-Alanine   4.45  
L-Asparagine   ---  
L-Asparagine-H2O  7.50  
L-Aspartic Acid   6.66  
L-Glutamic Acid  7.36  
L-Proline   5.76 
 
Antibiotics      
Pen G Na Salt (units)  100,000.00  
Strep Sulfate   50.00  
  
 
 
62 
 
Appendix B 
Raw Ct Values 
Raw Ct values are provided for Aurora Kinase B and β-actin. Raw CT Values were obtained as 
described in Chapter 2. Inverted CT values were calculated as: Inverted Ct = 40-Raw Ct.  
 
Aurora Kinase B  
  
Raw Ct 
Inverted 
Ct 
Std Error 
GV 33.409 6.591 0.110 
MII 33.294 6.706 0.335 
1 Cell 33.039 6.961 0.112 
2 Cell 35.514 4.486 0.341 
4 Cell 36.941 3.060   
Morula 33.769 6.231 0.169 
Blastocyst 34.911 5.089 0.138 
        
CC 38.969 1.031 0.033 
 
β-actin 
  
Raw Ct 
Inverted 
Ct 
Std Error 
GV 30.417 9.583 0.468 
MII 30.762 9.238 0.262 
1 Cell 30.293 9.707 0.153 
2 Cell 31.750 8.250 0.536 
4 Cell 34.847 5.153   
Morula 27.061 12.939 0.754 
Blastocyst 24.860 15.140 0.129 
        
CC 29.908 10.092 0.106 
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